These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16648510)

  • 61. Efficacy of a rehabilitation program using minor muscles in colorectal cancer patients with chemotherapy-induced neuropathy: preliminary study.
    Hong KS; Chung SS; Kim KH; Lee RA
    Korean J Clin Oncol; 2022 Jun; 18(1):11-16. PubMed ID: 36945329
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Electroacupuncture for chemotherapy-induced peripheral neuropathy: study protocol for a pilot multicentre randomized, patient-assessor-blinded, controlled trial.
    Kim JH; Kim EJ; Seo BK; Lee S; Lee S; Jung SY; Lee MH; Kim AR; Park HJ; Shin MS; Choi SM
    Trials; 2013 Aug; 14():254. PubMed ID: 23945074
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NON-INVASIVE EVALUATION OF NERVE CONDUCTION IN SMALL DIAMETER FIBERS IN THE RAT.
    Zotova EG; Arezzo JC
    Physiol J; 2013; 2013():. PubMed ID: 23580940
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage).
    Cunningham JE; Kelechi T; Sterba K; Barthelemy N; Falkowski P; Chin SH
    Support Care Cancer; 2011 Sep; 19(9):1473-6. PubMed ID: 21766161
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ixabepilone development across the breast cancer continuum: a paradigm shift.
    Ibrahim NK
    Cancer Manag Res; 2010 Jun; 2():169-79. PubMed ID: 21188108
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Microtubule-binding agents: a dynamic field of cancer therapeutics.
    Dumontet C; Jordan MA
    Nat Rev Drug Discov; 2010 Oct; 9(10):790-803. PubMed ID: 20885410
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
    Puhalla S; Brufsky A
    Biologics; 2008 Sep; 2(3):505-15. PubMed ID: 19707381
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neurological adverse effects caused by cytotoxic and targeted therapies.
    Schiff D; Wen PY; van den Bent MJ
    Nat Rev Clin Oncol; 2009 Oct; 6(10):596-603. PubMed ID: 19707193
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.
    Goel S; Goldberg GL; Kuo DY; Muggia F; Arezzo J; Mani S
    Ann Oncol; 2008 Dec; 19(12):2048-52. PubMed ID: 18644829
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
    Pronzato P
    Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
    Lee JJ; Low JA; Croarkin E; Parks R; Berman AW; Mannan N; Steinberg SM; Swain SM
    J Clin Oncol; 2006 May; 24(13):2084-91. PubMed ID: 16648510
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
    Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
    Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.